Proteasome inhibition: a new strategy in cancer treatment - PubMed (original) (raw)

Review

Proteasome inhibition: a new strategy in cancer treatment

J Adams et al. Invest New Drugs. 2000 May.

Abstract

The ubiquitin proteasome pathway is a highly conserved intracellular pathway for the degradation of proteins. Many of the short-lived regulatory proteins which govern cell division, growth, activation, signaling and transcription are substrates that are temporally degraded by the proteasome. In recent years, new and selective inhibitors of the proteasome have been employed in cell culture systems to examine the anti-tumor potential of these agents. This review covers the chemistry of selected proteasome inhibitors, possible mechanisms of action in cell culture and the in vivo examination of proteasome inhibitors in murine and human xenograft tumor models in mice. One inhibitor, PS-341, has recently entered Phase I clinical trials in cancer patients with advanced disease to further test the potential of this approach.

PubMed Disclaimer

References

    1. Genes Dev. 1999 Mar 1;13(5):505-10 - PubMed
    1. J Biol Chem. 1997 Dec 26;272(52):32731-4 - PubMed
    1. Genes Dev. 1995 Jul 1;9(13):1586-97 - PubMed
    1. Tissue Antigens. 1997 Aug;50(2):153-63 - PubMed
    1. Nature. 1995 Aug 10;376(6540):517-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources